Printer Friendly

Printed from http://www.researchandmarkets.com/reports/1801427

Oropharyngeal Cancer - Pipeline Review, Q2 2011

Description:

Oropharyngeal Cancer - Pipeline Review, Q2 2011

Summary

Global Markets Direct’s, 'Oropharyngeal Cancer - Pipeline Review, Q2 2011', provides an overview of the Oropharyngeal Cancer therapeutic pipeline. This report provides information on the therapeutic development for Oropharyngeal Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Oropharyngeal Cancer. 'Oropharyngeal Cancer - Pipeline Review, Q2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Oropharyngeal Cancer.
- A review of the Oropharyngeal Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Oropharyngeal Cancer pipeline on the basis of therapeutic class, route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Oropharyngeal Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Oropharyngeal Cancer pipeline depth and focus of Oropharyngeal Cancer therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Contents:

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Oropharyngeal Cancer Overview
Therapeutics Development
An Overview of Pipeline Products for Oropharyngeal Cancer
Oropharyngeal Cancer Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Oropharyngeal Cancer Therapeutics - Products under Investigation by Universities/Institutes
Oropharyngeal Cancer - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
HPPH - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Cetuximab + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Paclitaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiation Therapy + Cetuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + 5-Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Cisplatin + Cetuximab + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Autologous monocyte-derived dendritic cells transfected with DNA - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erlotinib + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
INGN 201 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Carboplatin + Fluorouracil + Radiotherapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
S-1 + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Minocycline - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Ad5CMV-p53 Gene + Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Docetaxel + Cisplatin + 5FU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cytochlor + Tetrahydrouridine + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Radiotherapy + cisplatin - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Panitumumab + Cisplatin + Fluorouracil + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cetuximab + Cisplatin + Docetaxel + 5-FU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + erlotinib hydrochloride - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Erlotinib Hydrochloride + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + paclitaxel + Radiation therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lapatinib Ditosylate + Capecitabine - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Taxotere + Cisplatin + 5-FU - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Docetaxel + Cisplatin + Fluorouracil + Carboplatin + Cetuximab + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cisplatin + Radiation Therapy - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Oropharyngeal Cancer Therapeutics - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Oropharyngeal Cancer, Q2 2011
Products under Development for Oropharyngeal Cancer – Comparative Analysis, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Number of Products under Investigation by Universities/Institutes, Q2 2011
Comparative Analysis by Late Stage Development, Q2 2011
Comparative Analysis by Mid Clinical Stage Development, Q2 2011
Comparative Analysis by Early Clinical Stage Development, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Discontinued Products

List of Figures
Number of Products under Development for Oropharyngeal Cancer, Q2 2011
Products under Development for Oropharyngeal Cancer – Comparative Analysis, Q2 2011
Products under Investigation by Universities/Institutes, Q2 2011
Late Stage Products, Q2 2011
Mid Clinical Stage Products, Q2 2011
Early Clinical Stage Products, Q2 2011
Assessment by Monotherapy Products, Q2 2011
Assessment by Combination Products, Q2 2011
Assessment by Route of Administration, Q2 2011
Assessment by Stage and Route of Administration, Q2 2011
Assessment by Molecule Type, Q2 2011
Assessment by Stage and Molecule Type, Q2 2011

Ordering:

Order Online - visit http://www.researchandmarkets.com/reports/1582661

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Page 1 of 2

Printed Saturday, May 25, 2013
6:49:00 PM

Fax order form

To place a fax order simply print this form, fill in and fax the completed form to the number below. If you have any questions please email help@researchandmarkets.net

Order information

Please verify that the product information is correct and select the format you require.

Product name

Oropharyngeal Cancer - Pipeline Review, Q2 2011

Web Address

http://www.researchandmarkets.com/reports/1801427

Office Code

OC8DIQSMMOWURR

Report Formats

Please enter the quantity of the report format you require.

Format	Quantity	Price
Electronic (PDF) - Single User		EURO€ 384.00
Electronic (PDF) - Site License		EURO€ 769.00
Electronic (PDF) - Enterprisewide		EURO€ 1,153.00

Contact information

Please enter all the information below in block capitals.

                Title:
            
                    Mr
                    
                    Mrs
                    
                    Dr
                    
                    Miss
                    
                    Ms
                    
                    Prof
                    
                First Name:
            
                Last Name:
                
                Email Address:
            
                Job Title:
            
                Organisation:
            
                Address:
            
                City:
            
                Postal / Zip Code:	
            
                Country:	
            
                Phone Number:	
            
                Fax Number:

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Page 2 of 2

Printed Saturday, May 25, 2013
6:49:00 PM

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

Pay by Credit Card:

American Express

Diners Club

Master Card

Visa

Cardholder's Name:

Cardholder's Signature:

Expiry Date:

Card Number:

CVV Security Code:

Issue date:

(Diners Club only)

Pay by Check:

Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.

Pay by Wire Transfer:

Please transfer funds to:

Account Number:

83313083

Sort Code:

98-53-30

Swift Code:

ULSBIE2D

IBAN Number:

IE78ULSB98533083313083

Bank Address:

Ulster Bank,
27-35 Main Street
Blackrock,
Co. Dublin
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code:

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Printer Friendly

Oropharyngeal Cancer - Pipeline Review, Q2 2011

Fax order form

Order information

Product name

Web Address

Office Code

Report Formats

Contact information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Payment information

Please fax this form to: (646) 607-1907 or (646) 964-6609 (from USA) +353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)